Ambuja Cements (AMBUJACEM) — Financial Results

Ambuja Cements reported consolidated revenue of ₹13,200 crores for Q4 FY2025, reflecting a 12% YoY growth, while net profit reached ₹1,200 crores, up 18% YoY. The company highlighted strong demand in infrastructure and housing segments driving volume expansion. Operational efficiency initiatives contributed to improved margins despite rising input costs. The management emphasized ongoing capacity optimization and sustainable growth strategies aligned with long-term infrastructure development goals in India.

📄 View Original Announcement (PDF)

📊 Stock Analysis — AMBUJACEM ✨ Ask AI About This

About Ambuja Cements Limited (AMBUJACEM)

Construction Materials · Cement & Cement Products · Listed on NSE

Market Cap: ₹1,07,215.34 Cr P/E: 23.3 ROE: 7.7% ROCE: 4.6%

View full AMBUJACEM stock details →

📡 Get AI alerts when AMBUJACEM files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track AMBUJACEM — Free

💡 Ask AI about this filing

"How does this financial results affect Ambuja Cements Limited's outlook?" "What did Ambuja Cements Limited announce on 23 April 2025?" "Is this positive or negative for AMBUJACEM?"

Ask AI Free →

📊 More AMBUJACEM filings

See all AMBUJACEM filings →

🔥 Also filed on 23 April 2025

BAJFINANCE Bajaj Finance Limited Financial Results ICICIPRULI ICICI Prudential Life Insurance Company Limited Corporate Action IGL Indraprastha Gas Limited Financial Results VBL Varun Beverages Limited Financial Results OFSS Oracle Financial Services Software Limited Board Meeting BEL Bharat Electronics Limited Board Meeting

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AMBUJACEM files new disclosures

Track AMBUJACEM filings, board meetings, and corporate actions. Free email alerts at 5 PM.